TP53 and cancer: In line, it has been demonstrated that TP53 mutants interact directly with NF-κB and that both factors impact the other's binding at diverse sets of active enhancers thus promoting a unique enhancer landscape of cancer cells in response to chronic inflammation (Rahnamoun et al., 2017).